Charles de Rohan becomes CEO of The Binding Site
This article was originally published in Clinica
Executive Summary
UK immunodiagnostics firm The Binding Site has appointed Charles de Rohan to the position of CEO. Mr de Rohan was previously the CEO of Genetix, a cell imaging and analysis firm that was acquired by Danaher in 2009. He has also worked for Abbott Laboratoires’ diagnostic division and began his career at Ernst & Young, where he trained as a chartered accountant. Birmingham-based The Binding Site is currently growing the international coverage of its leading product, the Freelite assay for diagnosis and monitoring of a cancer of cells in the bone marrow called multiple myeloma.